MedTrace Logo

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

NCT00935246 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2015-12-31

No results posted yet for this study

Summary

To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).

Conditions

  • Depression
  • Continuous Antidepressant Abuse
  • Adverse Reaction to Drug

Interventions

DRUG

Escitalopram

Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Doh Kwan Kim, PhD, M.D. · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-10-31
Completion
2016-12-31

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00935246 on ClinicalTrials.gov